Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders
CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 8, 2021.
The results of the director elections were as follows:
Name | Votes inFavor | % Votes inFavor | VotesWithheld | % VotesWithheld |
Mr. Luke Beshar | 45,690,551 | 89.6 | 5,331,299 | 10.4 |
Dr. Michael Kamarck | 50,875,937 | 99.7 | 145,912 | 0.3 |
Mr. Scott Myers | 50,879,347 | 99.7 | 142,503 | 0.3 |
Mr. Paolo Pucci | 50,842,785 | 99.7 | 179,065 | 0.3 |
Dr. Jan Skvarka | 50,903,051 | 99.8 | 118,798 | 0.2 |
Dr. Helen Tayton-Martin | 50,766,458 | 99.5 | 255,391 | 0.5 |
Mr. Paul Walker | 41,737,821 | 81.8 | 9,284,029 | 18.2 |
The shareholders of the Corporation also voted to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants as auditors of the Corporation for the ensuing year. In addition, the shareholders approved the non-binding, advisory vote on the compensation paid to the Corporation’s named executive officers and recommended that future advisory votes on the compensation paid to the Corporation’s named executive officers should be held every year. For complete voting results on all matters approved at the Meeting, please see the Corporation’s Report of Voting Results dated June 9, 2021 available on SEDAR at www.sedar.com and the Current Report on Form 8-K filed on EDGAR.
About Trillium Therapeutics Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-622 and TTI-621, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.
For more information visit: www.trilliumtherapeutics.com
Company Contact:Rosemary HarrisonSVP, Corporate Development and StrategyTrillium Therapeutics Inc. 416-595-0627 x225[email protected]www.trilliumtherapeutics.com
Media Relations:Mike BeyerSam Brown Inc.312-961-2502[email protected]
Source: Trillium Therapeutics Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HireRight, and Doximity Innovations and Encourages Investors to Contact the Firm
- Dicello Levitt LLP Announces Investor Class Action Lawsuit Filed Against QuidelOrtho Corp. f/k/a Quidel Corp. (NASDAQ: QDEL) And Lead Plaintiff Deadline
- Banco Itaú Chile Files Material Event Notice announcing Extraordinary General Shareholders’ Meeting Agreements
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!